Brief: Helixmith Announces Topline Results From Double-Blind Placebo Controlled Multicenter Study For TADIOS Involving 100 Subjects Infected With COVID-19
03/08/2022 11:41
Aug 3 (Reuters) - Helixmith Co Ltd 084990.KQ :
* HELIXMITH ANNOUNCES TOPLINE RESULTS FROM DOUBLE-BLIND
PLACEBO
CONTROLLED MULTICENTER STUDY FOR TADIOS INVOLVING 100 SUBJECTS
INFECTED WITH COVID-19
* HELIXMITH USA - TADIOS WAS DETERMINED TO BE SAFE AND WELL
TOLERATED
* HELIXMITH USA - SERUM LEVELS OF IL-1RA CHANGED
SIGNIFICANTLY,
BIOMARKER THAT HAS A CORRELATION WITH SEVERITY AND MORTALITY
DURING COVID-19 INFECTIONS
Source text for Eikon: ID:nPn6KvXGBa
Further company coverage: 084990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helixmith
See all newsBrief: Helixmith Announces Topline Results From Double-Blind Placebo Controlled Multicenter Study For TADIOS Involving 100 Subjects Infected With COVID-19
Brief: Helixmith Announces 50% Enrollment In Its Clinical Trial For COVID-19, Involving Tadios
Brief: ViroMed issues 2nd series convertible bonds worth 100 bln won
Brief: ViroMed appoints CEO
Brief: ViroMed receives patent